Abstract: Provided are a modified Na-montmorillonite and a preparation method thereof, wherein the content of Na+ in the modified sodium-montmorillonite, calculated as Na2O, is not less than 2.0%. The modified Na-montmorillonite has more reasonable microstructure, higher performance, and better quality. Also provided are a method for preparing a modified nanometered Na-montmorillonite from the modified Na-montmorillonite, and the modified nanometered Na-montmorillonite obtained by the method. Also provided are uses and a pharmaceutical composition of the modified Na-montmorillonite or modified nanometered Na-montmorillonite.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: A liquid composition comprising racecadotril and cyclodextrin.

Abstract: This invention provides compositions and methods for treating and vaccinating against an Her2/neu antigen-expressing tumor and inducing an immune response against dominant and several sub-dominant epitopes of the antigen.

Abstract: The present invention relates to pharmaceutical dosage forms, for example to a tamper resistant dosage form including an opioid analgesic, and processes of manufacture, uses, and methods of treatment thereof.

Abstract: A cosmetic transparent gel preparation that has high levels of transparency and hardness and favorable usability, as well as a gelling agent that is ideal for use in the cosmetic transparent gel preparation. The cosmetic transparent gel preparation contains an esterification reaction product obtained by reacting glycerol with a dibasic acid of 18 to 28 carbon atoms and a fatty acid of 8 to 28 carbon atoms (excluding dibasic acids), 12-hydroxystearic acid, and an oil component. The gelling agent contains an esterification reaction product obtained by reacting glycerol with a dibasic acid of 18 to 28 carbon atoms and a fatty acid of 8 to 28 carbon atoms (excluding dibasic acids), and 12-hydroxystearic acid.

Abstract: The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. Bacteriophage display technology was employed to identify peptides that bound to the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity selected population, was chemically synthesized and characterized for its binding activities to the recombinant extracellular domain of ErbB-2. The synthetic peptide exhibits high specificity to ErbB-2 as well as to ErbB-1, another member of ErbB family. Thus, this peptide can be employed in cancer imaging or therapeutic agent targeting to malignant cells ErbB-2 receptor.

Abstract: The present invention relates to the cosmetic, dermatological or pharmaceutical (therapeutic) use of compounds of formula (I) or a cosmetically acceptable salt of a compound of formula (I) or a mixture containing two or more of these compounds or the salts thereof wherein R1 denotes hydrogen or an organic radical having 1 to 14 carbon atoms, R2 denotes an organic radical having 1 to 14 carbon atoms, and wherein optionally R1 and R2 are covalently bonded to one another, preferably so that a 3 to 8 membered ring is formed, for the lightening of skin and/or hair. The invention further relates to compositions and cosmetic, dermatological or pharmaceutical preparations (compositions) comprising one or more compounds of formula (I) suitable for lightening human skin and/or hair and corresponding methods.

Abstract: The invention provides a method of determination of diagnosis and prognosis of B-cell chronic lymphocytic leukemia from a biological sample collected from the body of a patient, wherein the status of Wnt/PCP signaling pathway is determined. Within the framework of the present invention the relation of CLL and molecular signaling pathway Wnt/PCP the components of which are markedly up-regulated in B-lymphocytes of the patients suffering from CLL was identified. The status of the Wnt/PCP signaling pathway can be determined, e.g., by the determination of the expression of components of said signaling pathway or by the determination of migration of CLL cells in the gradient of a chemokine in the presence of the ligand of said signaling pathway. The invention also relates to suitable oligonucleotides for use in the method of determination of expression of the signaling pathway components.

Abstract: Embodiments of the present invention concern methods and compositions related to detection of ovarian cancer, including detection of the stage of ovarian cancer, in some cases. In particular, the invention encompasses use of expression of TFAP2A and in some embodiments CA125 and/or E2F5 to identify ovarian cancer, including detecting mRNA and/or protein levels of the respective gene products. Kits for detection of ovarian cancer are also described.

Abstract: Chimeric ErbB ligand binding molecules having detectable binding activity for more ErbB ligands than any one of native ErbB 1, ErbB3 or ErbB4 are disclosed. Preferably, the binding molecules bind a broad spectrum and, more preferably, the full spectrum of ErbB ligands. The chimeric ErbB ligand binding molecules generally have a subunit LI derived from one of ErbB1, 3, or 4 and a subunit LII derived from another distinct ErbB receptor type. The sub-domain, SI, which joins LI and LII can be from either one of the receptor types or can have portions from both. Pharmaceutical compositions that contain the molecules and methods for the treatment of ErbB sensitive diseases are also disclosed.

Abstract: The present disclosure relates to pharmaceutical compositions that are abuse resistant and may also provide controlled release. The present disclosure also relates to the use of pharmaceutical compositions in the treatment of pain.

Abstract: Use of 1,4-bis(3-aminoalkyl)piperazine derivatives as defined in formula I or II for the manufacture of a pharmaceutical composition intended for the treatment of neurodegenerative diseases, related neurodegenerative diseases, developmental diseases or cancer. The instant invention is also directed to some specific 1,4-bis(3-aminoalkyl)piperazine derivatives and pharmaceutical composition including them.

Abstract: This invention relates, e.g., to a composition comprising two or more of: (a) N-acetylcysteine and/or (b) simethicone and/or (c) a docusate salt. In one embodiment of the invention, the amounts of (a) and/or (b) and/or (c) are effective, when the composition is administered into a colon of a subject undergoing colonoscopy, to cleanse a region of the colon in the visual field of the colonoscope so that the region contains no adherent stool or intestinal secretions obscuring the visual field. Methods for using this or other compositions of the invention, e.g. to cleanse the colon of a subject in order to enhance visualization of the colon during a colonoscopy, are also described, as are kits for carrying out methods of the invention.

Abstract: Embodiments of topical formulations for administering compound I or a pharmaceutically acceptable salt or solvate thereof are disclosed. Embodiments of methods for using the topical formulations in the treatment of dermatological disorders such as cutaneous collagen vascular diseases, e.g., cutaneous lupus, also are disclosed.

Abstract: The invention is directed toward porous composites for application to a bone defect site to promote new bone growth. The inventive porous composites comprise a biocompatible polymer and a plurality of particles of bone-derived material, inorganic material, bone substitute material or composite material. In certain embodiments, the porous composites are prepared using a method that includes a supercritical fluid (e.g., supercritical carbon dioxide) treatment. The invention also discloses methods of using these composites as bone void fillers.

Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Abstract: The present inventors found that a fusion gene present in some cancer patients is an oncogene. The present invention relates to a polypeptide as a novel fusion protein, a polynucleotide encoding the polypeptide, a vector comprising the polynucleotide, a transformed cell comprising the vector, a method for detecting the fusion protein or polynucleotide, a method for screening a therapeutic agent for cancer, and a method for treating cancer that is shown to be positive for the fusion gene. Further, the present invention relates kit, primer set, and probe useful in the detection of cancer that is shown to be positive for the fusion gene.

Abstract: The present invention relates to a batch method for impregnating a nonporous polymer pharmaceutical carrier with an active substance, characterized in that said method includes the following consecutive steps: a) mixing the active substance and the nonporous polymer pharmaceutical carrier, the pharmaceutical carrier being in a solid form and insoluble in supercritical CO2 and not being non-crosslinked polyvinylpyrrolidone; b) performing a step of molecular diffusion in the absence of water by contacting, in a static mode without agitation, the mixture obtained in step a) with supercritical CO2 at a pressure of 80 to 170 bars, at a temperature of 31 to 90° C. for 1 to 6 hours; c) recovering the polymer pharmaceutical carrier impregnated with the active substance obtained in step b), the impregnated pharmaceutical carrier being nonporous and being in a solid form and the active substance being in an amorphous form, the method being implemented in the absence of an additional solvent.

Abstract: The present invention relates to pharmaceutical, nutraceutical, health foods and medical device compositions comprising polysaccharides from Opuntia Ficus Indica cladodes in combination with antioxidant and anti-inflammatory plant extracts as well as those from Olive leaf, Capparis Spinosa buttons, anthocianosides from red oranges, black rice or from other natural sources and their combinations, useful for prevention and therapy of hemorrhoidal disease and related diseases. The invention compositions may, be applied topically or administered by oral route.